Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Abstract

Background: The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time- of time-to-event (TTE) end points is rarely precise and lacks uniformity across trials. End point definition can impact trial results by affecting estimation of treatment effect and statistical power. The DATECAN initiative (Definition for the Assessment of Time-to-event End points in CANcer trials) aims to provide recommendations for definitions of TTE end points. We report guidelines for RCT in sarcomas and gastrointestinal stromal tumors (GIST). Methods:We first carried out a literature review to identify TTE end points ( primary or secondary) reported in publications of RCT. An international multidisciplinary panel of experts proposed recommendations for the definitions of these end points. Recommendations were developed through a validated consensus method formalizing the degree of agreement among experts.Results: Recommended guidelines for the definition of TTE end points commonly used in RCT for sarcomas and GIST are provided for adjuvant and metastatic settings, including DFS, TTF, time to progression and others.Conclusion: Use of standardized definitions should facilitate comparison of trials' results, and improve the quality of trial design and reporting. These guidelines could be of particular interest to research scientists involved in the design, conduct, reporting or assessment of RCT such as investigators, statisticians, reviewers, editors or regulatory authorities.

Robot‐assisted resection of gastrointestinal stromal tumors (GIST): a single center case series and literature review

“…In the paper published by Desiderio et al . , five patients with a mean age of 63.6 years (43–76) underwent robotic surgical resection for gastric GIST. Lesions were localized to the anterior wall of the gastric antrum in two patients and near the pyloric area in the other three.…”

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs

“…Progression‐free interval (PFI) was calculated for all dogs and defined as the time from the day of first toceranib treatment to the time of disease progression (defined as local recurrence, local progression, metastasis, or some combination of these), the time of death from any cause, or the time of data collection . For dogs with gross (measurable) disease, as in previous publications describing the use of toceranib in dogs, clinical benefit (CB) was determined by best response to treatment and was defined as complete response (CR) or partial response (PR) of any duration, or stable disease (SD) of at least 10 weeks in duration .…”

Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer

“…For ''cause of mortality" ascertained cases, misclassification is still possible during the study period with the interplay of disease recurrence, emergence of second primaries, treatment related toxicity, and other intercurrent diseases relevant to such patients. Bellera et al [38] recommended classifying cause of death into 5 categories in clinical trials according to: a). primary cancer/to progression, b).…”